Platelet-activating factor acetylhydrolase gene mutation in Japanese nephrotic children

Kidney International

Volumn 54, Issue 6, 1998, Pages 1867-1871

  Xu, Hong ^b   Iijima, Kazumoto ^b   Shiozawa, Shunichi ^b   Tanaka, Ryojiro ^b   Inoue, Yuji ^b   Shirakawa, Taku ^b   Nishiyama, Kaoru ^b   Miwa, Masao ^b   Nakamura, Hajime ^b   Yoshikawa, Norishige ^a  

^a KOBE UNIVERSITY   (Japan)

^b NONE

Author keywords

Gene mutation; Inflammation; Japanese children; PAF; Relapse of renal disease; Steroid responsive nephrotic syndrome

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; DNA; PREDNISOLONE; STEROID;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; POINT MUTATION; PRIORITY JOURNAL; RELAPSE;

EID: 7844244661     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00215.x     Document Type: Article

References (41)

1. PRESCOTT SM, ZIMMERMAN GA, MCINTYRE TM: Platelet-activating factor. J Biol Chem 265:17381-17384, 1990
2. IMAIZUMI TA, STAFFORINI DM, YAMADA Y, MCINTYRE TM, PRESCOTT SM, ZIMMERMAN GA: Platelet-activating factor: A mediator for clinicians. J Intern Med 238:5-20, 1995
3. BAZAN NG: A signal terminator. Nature 374:501-502, 1995
4. ZOJA C, REMUZZI G: Role of platelets in progressive glomerular diseases. Pediatr Nephrol 9:495-502, 1995
5. SCHLONDORFF D, NEUWIRTH R: Platelet-activating factor and the kidney. Am J Physiol 251:F1-F11, 1986
6. LIANOS EA, ZANGLIS A: Glomerular platelet-activating factor levels and origin in experimental glomerulonephritis. Kidney Int 37:736-740, 1990
7. PERICO N, DELAINI F, TAGLIAFERRI M, ABBATE M, CUCCHI M, BERTANI T, REMUZZI G: Effect of platelet-activating factor and its specific receptor antagonist on glomerular permeability to proteinuria in isolated perfused rat kidney. Lab Invest 58:163-171, 1988
8. CAMUSSI G, TETTA C, BUSSOLINO F, ANDRES G, TURELLO E, BAGLIONI C: Involvement of cytokines and platelet-activating factor in renal pathology. J Lipid Mediat 2:S203-213, 1990
9. EMANCIPATOR SN, SEDOR JR: Cytokines in renal disease, in Cytokines in diseases, edited by REMICK DG, KUNKEL SL, Boston, Marcel Dekkcr Press, 1992, pp 467-488
10. SANCHEZ CRESPO M, ALONSO F, INARREA P, ALVAREZ V, EGIDO J: Vascular actions of synthetic PAF-acether (a synthetic platelet-activating factor) in the rat: Evidence for a platelet-independent mechanism. Immunopharmacology 4:173-185, 1982
11. CAMUSSI G, TETTA C, CODA R, SEGOLONI GP, VERCELLONE A: Platelet-activating factor-induced loss of glomerular anionic charges. Kidney Int 25:73-81, 1984
12. STAFFORINI DM, PRESCOTT SM, MCINTYRE TM: Human plasma platelet-activating factor acetylhydrolase: Purification and properties. J Biol Chem 262:4223-4230, 1987
13. STAFFORINI DM, PRESCOTT SM, ZIMMERMAN GA, MCINTYRE TM: Platelet-activating factor acetylhydrolase activity in human tissues and blood cells. Lipids 26:979-985, 1991
14. TETTA C, BUSSOLINO F, MODENA V, MONTRUCCHIO G, SEGOLONI G, PESCARMONA G, CAMUSSI G: Release of platelet-activating factor in systemic lupus erythematosus. Int Arch Allergy Appl Immunol 91:244-256, 1990
15. GRAHAM RM, STEPHENS CJ, SILVESTER W, LEONG LL, STURM MJ, TAYLOR RR: Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis. Crit Care Med 22:204-212, 1994
16. MIWA M, MIYAKE T, YAMAOKA T, SUGATANI J, SUZUKI Y, SAKATA S, ARAKI Y, MATSUMOTO M: Characterization of serum platelet-activating factor (PAF) acetylhydrolase: Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest 82:1983-1991, 1988
17. STAFFORINI DM, SATOH K, ATKINSON DL, TJOELKER LW, EBERHARDT C, YOSHIDA H, IMAIZUMI T, TAKAMATSU S, ZIMMERMAN GA, MCINTYRE TM, GRAY PW: Platelet-activating factor acetylhydrolase deficiency: A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest 97:2784-2791, 1996
18. MEADOW SR, SARSFIELD JK: Steroid-responsive nephrotic syndrome and allergy: Clinical studies. Arch Dis Child 56:509-516, 1981
19. INTERNATIONAL STUDY OF KIDNEY DISEASE IN CHILDREN: Primary nephrotic syndrome in children: Clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. Kidney Int 20:765-771, 1981
20. INTERNATIONAL STUDY OF KIDNEY DISEASE IN CHILDRLN: Early identification of frequent relapsers among children with minimal change nephrotic syndrome. J Pediatr 101:514-518, 1982
21. Statview J-4.02 User Manual. Berkeley, Abacus Concepts. 1994
22. SPSS Base System Release 6.xJ. SPSS Inc., 1994
23. ZIMMERMAN GA, PRESCOTT SM, MCINTYRE TM: Platelet-activating factor: A fluid phase and cell-associated mediator of inflammation, in Inflammation: Basic Principles and Clinical Correlates (2nd ed), edited by GALLIN JI, GOLDSTEIN IM, SNYDERMAN R, New York, Raven Press, 1992, pp 149-176
24. BERTANI T, LIVIO M, MACCONI D, MORIGI M, BISOGNO G, PATRONO C, REMUZZI G: Platelet activating factor (PAF) as a mediator of injury in nephrotoxic nephritis. Kidney Int 31:1248-1256, 1987
25. CAMUSSI G, PAWLOWSKI I, SAUNDERS R, BRENTJENS J, ANDRES G: Receptor antagonist of platelet activating factor inhibits inflammatory injury induced by in situ formation of immune complexes in renal glomeruli and in the skin. J Lab Clin Med 110:196-206, 1987
26. GOMEZ-CHIARRI M, ORTIZ A, LERMA JL, LOPEZ-ARMADA MJ, MAMPASO F, GONZALEZ E, EGIDO J: Involvement of tumor necrosis factor and platelet-activating factor in the pathogenesis of experimental nephrosis in rats. Lab Invest 70:449-459, 1994
27. HUSENYINOV A, KANTAR M, MIR S, COKER I, KABASAKAL C, CURA A: Does platelet activating factor (PAF) have a role in steroid sensitive nephrotic syndrome? Acta Pediatr Jpn 40:57-62, 1998
28. NORIS M, BENIGNI A, BOCCARDO P, GOTTI E, BENFENATI E, AIELLO S, TODESCHINI M, REMUZZI G: Urinary excretion of platelet activating factor in patients with immune-mediated glomerulonephritis. Kidney INT 43:426-429, 1993
29. BENIGNI A, BOCCARDO P, NORIS M, REMUZZI G, SIEGLER RL: Urinary excretion of platelet-activating factor in haemolytic uraemic syndrome. Lancet 339:835-836, 1992
30. MEZZANO S, KUNICK M, OLAVARRIA F, ARDILES L, MONTRUCCHIO G, SILVESTRO L, BIANCONE L: Detection of platelet-activating factor in plasma of patients with streptococcal nephritis. J Am Soc Nephrol 4:235-242, 1993
31. BUSTOS C, GONZALEZ E, GONZALEZ-CUADRADO S, ORTIZ A, MULEY R, DE NICOLAS R, PLAZA JJ, EGIDO J: Urinary excretion of platelet-activating factor in human and experimental nephrosis. Nephrol Dial Transplant 11:282-286, 1996
32. ASANO K, TANIGUCHI S, NAKANO A, WATANABE T, KUROKAWA K: Distribution of platelet activating factor receptor mRNA along the rat nephron segments. Biochem Biophys Res Commun 225:352-57, 1996
33. STAFFORINI DM, ROLUNS EN, PRESCOTT SM, MCLNTYRE TM: The platelet-activating factor acetylhydrolase from human erythrocytes: Purification and properties. J Biol Chem 268:3857-65, 1993
34. KIRSCHBAUM B: Platelet activating factor acetylhydrolase activity in the urine of patients with renal disease. Clin Chim Acta 199:139-46, 1991
35. TJOELKER LW, WILDER C, EBERHARDT C, STAFFORINI DM, DIETSCH G, SCHIMPF B, HOOPER S, TRONG HL, COUSENS LS, ZIMMERMAN GA, YAMADA Y, MCINTYRE TM, PRESCOTT SM, GRAY PW: Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 374:549-553, 1995
36. THOMSON PD, BARRATT TM, STOKES CR, TURNER MW, SOOTHILL JF: HLA antigens and atopic features in steroid-responsive nephrotic syndrome of childhood. Lancet 2:765-768, 1976
37. MEYERS K, KUJUBU D, KAPLAN B: Minimal-change nephrotic syndrome, in Immunologic Renal Diseases, edited by NEILSON EG, COUSER WG, Philadelphia, Lippincott-Raven Publishers, 1997, pp 975-992
38. LEISTI S, HALLMAN H, KOSKIMIS O, PERHEENTUPA J, RAPOLA J, VILSKA J: Association of postmedication hypocortisolism with early first relapse of idopathic nephrotic syndrome. Lancet 2:795-796, 1977
39. SHALHOUB RJ: Pathogenesis of lipoid nephrosis: A disorder of T -cell function. Lancet 2:556-60, 1974
40. LAGRUE G, XHENEUMONT S, BRANELLEC A, HIRBEC G, WEIL B: A vascular permeability factor elaborated from lymphocytes: I. Demonstration in patients with nephrotic syndrome. Biomedicine 23:37-40, 1975
41. SIROIS MG, EDELMAN ER: VEGF effect on vascular permeability is mediated by synthesis of platelet-activating factor. Am J Physiol 41:H2746-H2756, 1997